Patents by Inventor Scott BRAUNSTEIN

Scott BRAUNSTEIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders
    Patent number: 12390477
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 3, 2024
    Date of Patent: August 19, 2025
    Assignee: Immedica Pharma US Inc.
    Inventors: Joseph Hulihan, Alex Aimetti, Scott Braunstein
  • Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders
    Patent number: 12383564
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 3, 2024
    Date of Patent: August 12, 2025
    Assignee: Immedica Pharma US Inc.
    Inventors: Joseph Hulihan, Alex Aimetti, Scott Braunstein
  • Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders
    Patent number: 12268696
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 3, 2024
    Date of Patent: April 8, 2025
    Assignee: Marinus Pharmaceuticals, Inc.
    Inventors: Joseph Hulihan, Alex Aimetti, Scott Braunstein
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS
    Publication number: 20250032512
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 10, 2024
    Publication date: January 30, 2025
    Inventors: Joseph HULIHAN, Alex AIMETTI, Scott BRAUNSTEIN
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS
    Publication number: 20250025477
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 3, 2024
    Publication date: January 23, 2025
    Inventors: Joseph HULIHAN, Alex AIMETTI, Scott BRAUNSTEIN
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS
    Publication number: 20250025476
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 3, 2024
    Publication date: January 23, 2025
    Inventors: Joseph HULIHAN, Alex Aimetti, Scott Braunstein
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS
    Publication number: 20250025475
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 3, 2024
    Publication date: January 23, 2025
    Inventors: Joseph HULIHAN, Alex AIMETTI, Scott BRAUNSTEIN
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX
    Publication number: 20240374614
    Abstract: The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.
    Type: Application
    Filed: February 29, 2024
    Publication date: November 14, 2024
    Inventors: Alex AIMETTI, Joseph HULIHAN, Scott BRAUNSTEIN
  • Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders
    Patent number: 12115169
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 5, 2024
    Date of Patent: October 15, 2024
    Assignee: Marinus Pharmaceuticals, Inc.
    Inventors: Joseph Hulihan, Alex Aimetti, Scott Braunstein
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS
    Publication number: 20240173336
    Abstract: The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 5, 2024
    Publication date: May 30, 2024
    Inventors: Joseph HULIHAN, Alex AIMETTI, Scott BRAUNSTEIN
  • Ganaxolone for use in treating tuberous sclerosis complex
    Patent number: 11980625
    Abstract: The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.
    Type: Grant
    Filed: April 26, 2023
    Date of Patent: May 14, 2024
    Assignee: Marinus Pharmaceuticals, Inc.
    Inventors: Alex Aimetti, Joseph Hulihan, Scott Braunstein
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX
    Publication number: 20240100067
    Abstract: The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.
    Type: Application
    Filed: April 26, 2023
    Publication date: March 28, 2024
    Inventors: Alex AIMETTI, Joseph HULIHAN, Scott BRAUNSTEIN
  • Ganaxolone for use in treating tuberous sclerosis complex
    Patent number: 11701367
    Abstract: The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: July 18, 2023
    Assignee: Marinus Pharmaceuticals, Inc.
    Inventors: Alex Aimetti, Joseph Hulihan, Scott Braunstein
  • GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX
    Publication number: 20220211723
    Abstract: The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.
    Type: Application
    Filed: March 1, 2022
    Publication date: July 7, 2022
    Inventors: Alex AIMETTI, Joseph HULIHAN, Scott BRAUNSTEIN